NLRP3 and inflammation: Other research demonstrates that ibrutinib reduces the activation of NF-κB and NLRP3 inflammasomes by targeting BTK and finally ameliorates pulmonary inflammation [37], suggesting that BTK might be a potential drug target for anti-inflammation.